about_MBC

Looking for patient-centered medicine
#metastaticBC

[METUPUK @METUPUKorg]

It is with profound sadness that we share the heartbreaking news that our beloved founder, Jo Taylor, died early on Monday morning surrounded by her husband Jeff, and two children, Regan and Faron.

Jo was a tireless advocate, a fearless campaigner and a beacon of hope for those living with metastatic breast cancer. Diagnosed with primary breast cancer in 2007 and with metastatic breast cancer in 2014, Jo dedicated her life to changing the narrative around MBC. She founded METUPUK and created the powerful #BusyLivingWithMets movement to show the world that people with MBC are living, thriving and worth the investment. 

Jo’s legacy is one of courage and unwavering determination. Her work has touched countless lives both here in the UK and around the world. From her advocacy and public speaking to the creation of the red flag signs and symptoms infographics, she undoubtedly paved the way to empower others to find their voice. 

She championed change with unwavering resolve and spoke with unflinching honesty. Jo’s voice lives on; her messages echo louder than ever: we demand change. 

Our thoughts are with Jo’s family, friends, and the entire MBC community. She will be deeply missed and absolutely never forgotten. 

She had the heart of a lioness. Rest in power, Jo 💔 

#JoTaylor #METUPUK #LegacyOfChange #MetastaticBreastCancer #MBCAdvocate #Stage4NeedsMore #BreastCancerAwareness #METUPUKCampaign #InMemory #PatientAdvocacy #KeepTalkingMBC #HonouringJoTaylor #WomenWhoInspire #NeverStopFighting

[Yale Cancer Center @YaleCancer]

Research led by Dr. Lajos Pusztai @YaleBreast finds pts with stage I/II #breastcancers have excellent prognosis, yet account for >60% of breast cancer-specific death because of the high number of patients who present with #earlystage disease. The importance of adequate treatment should be emphasized even for #lowrisk cancers. #bcsm
https://t.co/kRlNlf8sTC
@SmilowCancer @YaleMed @YNHH @MariyaRozenblit @maryam_lustberg @AdrianaKahnMD @JNCI_Now

[Vivek Subbiah, MD @VivekSubbiah]

🚨⭐️Check out my latest article: "Clinical Trial Fact v. Fiction"
https://t.co/mmGx2z1QHW via @LinkedIn @OncoAlert @SarahCannonDocs @ErikaHamilton9 @IshwariaMD @BurrisSkip @DavidRSpigel @BldCancerDoc

[Janice Cowden @JaniceTNBCmets]

Advocates for #MetastaticBreastCancer - @metavivor Stage IV Stampede in-person advocacy event is October 8 - 9th Washington, D.C. Your opportunity to share your story w. legislators, advance MBC research & improve access to quality healthcare & benefits for people living w. MBC.
For more information https://t.co/jgDOkjUeLJ & registration👉🏻 https://t.co/Bwfv5EvJBb
Use code MV9 for hotel block by September 9th‼️
#bcsm
#policyadvocacy
#legislativeadvocacy
#cancer
#research

[OurMBCLife @ourmbclife]

Today's episode is a rebroadcast from SHARE Cancer Support on #ASCO2024, featuring the latest in HR+ MBC, including insights from @KalinskyKevin on DESTINY-Breast06 & postMONARCH trials. @WinshipAtEmory
🎧 Listen (all channels) or 🔗 https://t.co/5jSlMkekyl
#MBCResearch #BCSM

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

This cross-sectional investigation looked at arm morbidity and financial difficulty in #BreastCancer survivors. Read it here: https://t.co/fdwbiODC6M
@dr_laurad @EMittendorfMD @TariKingMD

[Yale Cancer Center @YaleCancer]

We’re excited to announce @DrEricWiner as host of #YaleCancerAnswers, our weekly, award-winning radio show broadcast on @wnpr Sunday nights at 7:30pm. Stream anytime on @ApplePodcasts and @YouTube.
https://t.co/kK08YZgfPU
@SmilowCancer @YaleMed @YNHH

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

"I come to you today to speak about the harms of medical debt as an expert in the field, and also as someone with personal experiences with the financial devastation that patients & families feel after a cancer diagnosis."

Honored to testify in DC today:
https://t.co/CVGvBQOCMU

[PIK3CA Path Breakers @PIK3CApathbreak]

To say that we are heartbroken about losing our dear Marlena @MarlenaDM to MBC, is an understatement! Words alone cannot contain our feelings. Please remember her family and friends in the days ahead. And, can we please find a CURE for MBC! #bcsm

[David S Chang @dschan02]

@NiuSanford 100% true. Palliative care should be *palliative* in intent.

If it is life-prolonging then that's fantastic, but using OS as a primary endpoint is setting yourself up for failure.

[Dr. Nina Niu Sanford @NiuSanford]

Like I’ve argued re: RT in certain settings, I don’t think OS is the right endpoint for palliative care interventions.

It became a benchmark after the Temel study (results which haven’t been replicated to my knowledge) but expecting palliative care to improve OS in patients with incurable cancer is a stretch IMO.

Time toxicity, better informed decision making, cost, pain, quality of life – these are potential benefits of palliative care I see and discuss with my patients.

[Kevin Punie @kevinpunie]

@PTarantinoMD Nice overview! I can add SONIA with mPFS with fulvestrant after AI-palbociclib of 6.3 months.
I think whether or not pts with non-measurable evaluable disease are included (as in SONIA and postMonarch) might impact how PFS is judged in trials, in addition to scanning frequency

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Join Dr Sara Tolaney (@stolaney1) on June 26 for an important conversation on Hispanic and Latina triple negative #BreastCancer (#TNBC). Learn about the latest treatment options in this free #CME program with @medliveofficial, @SaludAmerica and @SBC_org
👉https://t.co/kT3U3Zr68b

[Kevin Kalinsky, MD, MS, FASCO @KalinskyKevin]

Very much looking forward to this! @DrNeilLove @hmcarthur @WinshipAtEmory #bcsm

[Jill Feldman @jillfeldman4]

TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
TOXICITY is the top reason for checkpoint inhibitor discontinuation
#ASCO24

[Hope Rugo @hoperugo]

However, this is a different population than registration trials. These patients had primary and secondary ET resistance. Trials with this population show short PFS with AI/CDKi. @OncoAlert

[Dr Sarah Sammons @drsarahsam]

As I try to figure out INAVO120, I would like to point out that patients with PIK3CA mutations do very well on first line Abema/Fulv or Ribo/Fulv with median PFS beyond 16 months in registrational trials.

Palbo/Fulv as a control arm is questionable

Thanks @Larvol for dataset.

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

PostMonarch: Abemaciclib after progression on CDK4/6 inhib shows 27% reduction in PFS. All subgroups, all biomarkers seem to benefit.

Valuable in the current landscape; sets the stage for EMBER-3 w/oral SERD + CDK4/6 and allows maximal ET in MBC

#ASCO24 @OncoAlert (COI/author)

[Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO @tomleblancMD]

If you missed the @ASCO Voices session yesterday, don't worry, you can still enjoy these powerful stories. Check out all 5 amazing narratives here: https://t.co/f7gYTr3Ben

My closing reflections are included as well, after Dr Leiter's presentation. I hope these touching stories stay with you throughout this conference and beyond, and that they inspire and center us all in recognizing the remarkable meaning and connection inherent in all that is cancer care.

Thank you to these amazing speakers for helping us set the tone for the start of #ASCO24, as we focus in these coming days on @ASCOPres theme of "The Art and Science of Cancer Care: from Comfort to Cure."

@AngieDemichele @cardismith @ErikaHamilton9
#hapc #pallonc #narrativemedicine #patientexperience

[Laila Agrawal, MD @LailaAgrawalMD]

#ASCO24: Abstracts on Sexuality in Female Cancer Survivors

Sexual health after cancer is too often ignored, esp in women - don't miss these abstracts!

@Areejmd @drteplinsky @Seamusoreilly18 @drdonsdizon @DrJennyReese @DrSharonBober @NarjustFlorezMD @matteolambe @ASCO